About Prothea Technologies
Prothea Technologies is a company based in Edinburgh (United Kingdom) founded in 2024. Prothea Technologies has raised $12.67 million across 1 funding round from investors including NRW.Bank, Earlybird and Merieux Equity Partners. Prothea Technologies operates in a competitive market with competitors including Prana Thoracic, Selio Medical, Suzhou Lung Care Medical Technologies, Spiromagic and Cirrus Bio, among others.
- Headquarter Edinburgh, United Kingdom
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Prothea Technologies Limited
- Date of Incorporation 14 Jun, 2021
- Jurisdiction EDINBURGH, SCOTLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12.67 M (USD)
in 1 rounds
-
Latest Funding Round
$12.67 M (USD), Series A
Apr 10, 2024
-
Investors
NRW.Bank
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Prothea Technologies
Prothea Technologies has successfully raised a total of $12.67M through 1 strategic funding round. The most recent funding activity was a Series A round of $12.67 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $12.7M
-
First Round
First Round
(10 Apr 2024)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Series A - Prothea Technologies | Valuation | Earlybird , Merieux Equity Partners |
Investors in Prothea Technologies
Prothea Technologies has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include NRW.Bank, Earlybird and Merieux Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Earlybird is recognized as a venture capital investor focused on early-stage tech companies.
|
Founded Year | Domain | Location | |
|
Pivate equity firm that focuses on investing in healthcare and nutrition companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
Investments & Acquisitions by Prothea Technologies
Financial Statements - Prothea Technologies
Prothea Technologies Comparisons
Competitors of Prothea Technologies
Prothea Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prana Thoracic, Selio Medical, Suzhou Lung Care Medical Technologies, Spiromagic and Cirrus Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
A company focused on early intervention in lung cancer.
|
|
| domain | founded_year | HQ Location |
Device developed to prevent pneumothorax during lung biopsies.
|
|
| domain | founded_year | HQ Location |
A bronchoscope navigation system is developed using electromagnetic positioning technology.
|
|
| domain | founded_year | HQ Location |
Smartphone-connected spirometers are supplied for lung function assessment.
|
|
| domain | founded_year | HQ Location |
Multi-omic solutions for disease diagnosis and management are developed.
|
Frequently Asked Questions about Prothea Technologies
Prothea Technologies was founded in 2024.
Prothea Technologies is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Crispin Simon is the current CEO of Prothea Technologies.
Prothea Technologies is a funded company, having raised a total of $12.67M across 1 funding round to date. The company's 1st funding round was a Series A of $12.67M, raised on Apr 10, 2024.
Prothea Technologies was founded in 2024 in Edinburgh, United Kingdom. Medical devices for lung cancer biopsy and treatments are developed by the company within the healthcare sector. A microendoscope combined with an image processing system is being created to enable in situ analysis of lesion structures at a molecular level. Enhanced visualization during procedures is facilitated through this technology, with operations centered on diagnostic and therapeutic applications.
Prothea Technologies's top competitors include Prana Thoracic, Selio Medical and Spiromagic.
Prothea Technologies has 4 investors. Key investors include NRW.Bank, Earlybird, Merieux Equity Partners, and Old College Capital.